Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Relugolix Versus Leuprolide in Patients With Prostate Cancer: A Randomized, Open-Label Study to Assess Major Adverse Cardiovascular Events (REPLACE-CV)

Next Previous
Trial Profile

Relugolix Versus Leuprolide in Patients With Prostate Cancer: A Randomized, Open-Label Study to Assess Major Adverse Cardiovascular Events (REPLACE-CV)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Sep 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Relugolix (Primary) ; Leuprorelin; Leuprorelin
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions; Registrational
  • Acronyms REPLACE-CV
  • Sponsors Myovant Sciences; Sumitomo Pharma America

Most Recent Events

  • 04 Apr 2025 Status changed from active, no longer recruiting to completed.
  • 01 May 2024 Planned End Date changed from 28 Feb 2027 to 31 Dec 2024.
  • 01 May 2024 Planned primary completion date changed from 28 Feb 2027 to 31 Dec 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top